Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Leporte

Family Medicine Laurinburg, NC Doctor of Osteopathy

NPI 1356721831 CMS profile 1321461

700A Progress Pl, Laurinburg, NC 28352

Open in the dashboard

General payments

$5,750

344 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Leporte of Laurinburg, NC is reported in the CMS Open Payments database as having received $5,750 across 344 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,072 71
2024 General $851 40
2023 General $1,425 90
2022 General $556 36
2021 General $694 44
2020 General $384 24
2019 General $768 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Leporte
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Andrew Leporte were reported at $1,072. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Andrew Leporte Family Medicine median Middle half National median
2019 $768 $150 $41–$543 $163
2020 $384 $120 $32–$415 $114
2021 $694 $137 $35–$551 $132
2022 $556 $137 $37–$512 $149
2023 $1,425 $149 $42–$545 $160
2024 $851 $156 $44–$560 $164
2025 $1,072 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,247 74 payments
  2. AstraZeneca Pharmaceuticals LP $693 38 payments
  3. AbbVie, Inc. $574 28 payments
  4. Amgen Inc. $386 39 payments
  5. Lilly USA, LLC $363 22 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $337 18 payments
  7. Pfizer Inc. $303 23 payments
  8. Sanofi-Aventis U.S. LLC $184 11 payments
  9. Ardelyx, Inc. $168 8 payments
  10. GlaxoSmithKline, LLC. $165 11 payments
  11. Other $1,331 72 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,750 344 payments
Products named General payments · program years 2019–2025
  1. Ozempic $627 37 payments
  2. RYBELSUS $525 37 payments
  3. FARXIGA $473 23 payments
  4. Otezla $311 33 payments
  5. VRAYLAR $308 10 payments
  6. BREZTRI $236 11 payments
  7. NURTEC ODT $218 17 payments
  8. Repatha $211 17 payments
  9. ELIQUIS $197 13 payments
  10. Wegovy $186 13 payments
  11. Other $4,354 266 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 183 drugs

Part D claims

10,746

Median for Family Practice: 1,826

Drug cost

$1,780,106

Median for Family Practice: $120,094

Branded share of claims

26.4%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 271 $330,443
Ozempic Semaglutide Brand 190 $242,478
Jardiance Empagliflozin Brand 110 $150,927
Eliquis Apixaban Brand 139 $138,683
Farxiga Dapagliflozin Propanediol Brand 99 $115,770
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 87 $68,215
Trulicity Dulaglutide Brand 62 $66,361
Linzess Linaclotide Brand 55 $65,707
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 55 $57,304
Rybelsus Semaglutide Brand 29 $40,899

The 10 drugs with the highest cost, of 183 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
$71 99 —
IBSRELA
$65 — —
JARDIANCE
$64 110 —
Wegovy
$61 — —
Heplisav-B
$52 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

344 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record